Japan PPI inflation slips to 11-mth low in July
WEXFORD, Pa. - Coeptis, Inc. (NASDAQ: COEP), a biopharmaceutical and technology company whose stock has surged over 210% in the past six months according to InvestingPro data, has announced a strategic partnership with MarketLeverage, a top digital advertising firm. This collaboration aims to enhance affiliate marketing by integrating artificial intelligence (AI) technology with performance-based strategies.
The partnership leverages MarketLeverage’s industry expertise and the NexGenAI Affiliates Network’s AI-powered platform, which Coeptis recently acquired. Trading near its 52-week high of $13.70, the company’s joint effort is poised to provide affiliates, brands, and marketers with advanced automation, data-driven insights, and campaign optimization tools.
Shane Hackett, CEO of MarketLeverage, expressed enthusiasm about the transformative potential of combining AI with affiliate marketing. Dave Mehalick, CEO of Coeptis Therapeutics Holdings Inc., echoed this sentiment, highlighting the opportunity to scale marketing efforts and drive engagement through this alliance.
The NexGenAI Affiliates Network enables affiliates to earn commissions through automated content distribution, social media sharing, and targeted email campaigns, optimizing performance in real-time with AI technology. The partnership is expected to offer affiliates an enhanced suite of tools for campaign management, predictive analytics, and automated outreach. Advertisers are anticipated to see increased visibility, higher conversion rates, and improved return on investment.
This initiative comes as the AI in marketing market size is projected to grow significantly, from $27.83 billion in 2024 to $35.54 billion in 2025, and further to $106.54 billion in 2029, according to market research. InvestingPro analysis reveals that while Coeptis operates with moderate debt levels, analysts don’t expect profitability this year. InvestingPro subscribers have access to 13 additional key insights about COEP’s financial health and market position.
Coeptis, with its subsidiaries, focuses on developing cell therapy platforms for various diseases and has recently ventured into the AI marketplace. MarketLeverage has established itself as an influential player in performance marketing, collaborating with thousands of advertisers and publishers.
The partnership underscores both companies’ commitment to innovation and efficiency in digital marketing. As AI continues to influence the sector, this collaboration ensures that involved parties remain at the forefront of the industry’s evolution. With a current market capitalization of $27.4 million and a beta of -0.81, Coeptis shows potential for growth independent of broader market movements.
The information for this article is based on a press release statement from Coeptis Therapeutics.
In other recent news, Coeptis Therapeutics Holdings, Inc. has announced several significant developments. The company has secured a convertible promissory note worth $1.1 million from YA II PN, LTD, with an annual interest rate of 8%, and a maturity date set for December 31, 2025. Additionally, Coeptis has completed a Series A Preferred Stock issuance, raising approximately $10 million, with investments from board member Christopher Calise, among others. In a strategic move, Coeptis has launched COEP Venture Group to invest in startups focused on AI, Robotic Process Automation, and AI Agents, with Michael Woloshin leading the initiative.
The company also reported securing five new clients for its NexGenAI Affiliates Network platform, bringing in managed services agreements valued at $1.25 million and an expected $450,000 in recurring monthly revenue. Coeptis is undergoing a rebrand to COEPTIS, signaling a shift towards integrating technology and AI into its operations, highlighted by the recent acquisition of the NexGenAI Affiliates Network platform. Furthermore, Coeptis has announced a 1-for-20 reverse stock split of its common stock, effective December 31, 2024, aiming to meet Nasdaq’s minimum bid price requirement. These developments reflect Coeptis’s ongoing strategic efforts to expand its technological capabilities and financial positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.